| Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management S Shimony, M Stahl, RM Stone American Journal of Hematology 98 (3), 502-526, 2023 | 130 | 2023 |
| Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors O Icht, N Darzi, S Shimony, O Jacobi, D Reinhorn, Y Landman, R Mutai, ... Journal of Thrombosis and Haemostasis 19 (5), 1250-1258, 2021 | 44 | 2021 |
| Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies I Amitai, U Rozovski, R El‐Saleh, S Shimony, D Shepshelovich, ... Hematological oncology 38 (4), 584-588, 2020 | 34 | 2020 |
| FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma I Vaxman, H Bernstine, G Kleinstern, N Hendin, S Shimony, ... Hematological Oncology 37 (2), 168-175, 2019 | 28 | 2019 |
| Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study O Pasvolsky, S Shimony, R Ram, A Shimoni, L Shargian-Alon, B Avni, ... Blood 138 (Supplement 1), 3962-3962, 2021 | 24 | 2021 |
| Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes S Shimony, RM Stone, M Stahl Current Opinion in Hematology 29 (2), 63-73, 2022 | 21 | 2022 |
| Safety and efficacy of blinatumomab: a real world data A Apel, Y Ofran, O Wolach, S Shimony, R Ram, I Levi, M Zektser, ... Annals of Hematology 99, 835-838, 2020 | 21 | 2020 |
| Romidepsin treatment for relapsed or refractory peripheral and cutaneous T‐cell lymphoma: Real‐life data from a national multicenter observational study S Shimony, N Horowitz, E Ribakovsky, U Rozovski, A Avigdor, K Zloto, ... Hematological Oncology 37 (5), 569-577, 2019 | 21 | 2019 |
| Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia S Shimony, Y Liu, YK Valtis, JD Paolino, AE Place, AM Brunner, ... Blood Advances 7 (7), 1092-1102, 2023 | 15 | 2023 |
| Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: A real-world analysis O Wolach, A Frisch, L Shargian, M Yeshurun, A Apel, V Vainstein, ... Annals of Hematology 101 (8), 1719-1726, 2022 | 14 | 2022 |
| Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis O Pasvolsky, S Shimony, M Yeshurun, L Shargian, O Wolach, P Raanani, ... Acta oncologica 60 (10), 1335-1341, 2021 | 14 | 2021 |
| Apixaban levels in octogenarian patients with non-valvular atrial fibrillation R Nissan, G Spectre, A Hershkovitz, H Green, S Shimony, L Cooper, ... Drugs & Aging 36, 165-177, 2019 | 14 | 2019 |
| Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax JP Bewersdorf, RM Shallis, A Derkach, AD Goldberg, A Stein, EM Stein, ... Leukemia Research 122, 106942, 2022 | 10 | 2022 |
| Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children O Gilad, O Dgany, S Noy-Lotan, T Krasnov, J Yacobovich, R Rabinowicz, ... Haematologica 107 (9), 2081, 2022 | 10 | 2022 |
| Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials S Shimony, Y Flamand, YK Valtis, AE Place, LB Silverman, LM Vrooman, ... Blood Advances 7 (18), 5234-5245, 2023 | 9 | 2023 |
| Late onset neutropenia after rituximab and obinutuzumab treatment–characteristics of a class-effect toxicity S Shimony, E Bar-Sever, T Berger, G Itchaki, R Gurion, M Yeshurun, ... Leukemia & lymphoma 62 (12), 2921-2927, 2021 | 9 | 2021 |
| Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy J Versluis, M Pandey, Y Flamand, JE Haydu, R Belizaire, M Faber, ... Blood Advances 6 (9), 2835-2846, 2022 | 8 | 2022 |
| Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI … YK Valtis, Y Flamand, S Shimony, AE Place, LB Silverman, LM Vrooman, ... Leukemia 38 (3), 482-490, 2024 | 7 | 2024 |
| Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors JP Bewersdorf, RM Shallis, A Derkach, AD Goldberg, A Stein, EM Stein, ... Leukemia & lymphoma 64 (1), 188-196, 2023 | 7 | 2023 |
| Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis S Shimony, J Canaani, E Kugler, B Nachmias, R Ram, I Henig, A Frisch, ... Annals of Hematology 101 (9), 2001-2010, 2022 | 7 | 2022 |
